Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current drugs which are used to treat breast cancer focus on the reduction of the tumor size and have proven to be successful. However, currently there are no available treatment options which can effectively inhibit tumor invasion and metastasis. Novel drug strategies therefore are needed to treat this chronic, fatal and incurable condition. Our therapeutic strategy for the treatment of aggressive breast cancer is based on reducing Id-1 expression. In the Phase 1 segment of this Fast-Track proposal our focus will be on developing lead compounds that display a favorable in vivo profile. In Phase II segment of this proposal our lead compounds will be evaluated in multiple in vivo models. We will also develop leads that display a favorable ADME-Tox profile. The ultimate goal of this proposal is to develop a novel therapeutic approach for the treatment of metastatic human breast cancers by down-regulation of Id-1.

Public Health Relevance

Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. Currently there are no available treatment options which can effectively inhibit tumor invasion and metastasis. The goal of this proposal is to develop a non-toxic medication for the treatment and prevention of metastatic breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44CA206723-01A1
Application #
9201646
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Haim, Todd E
Project Start
2016-09-01
Project End
2017-02-28
Budget Start
2016-09-01
Budget End
2017-02-28
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Organix, Inc.
Department
Type
DUNS #
161843057
City
Woburn
State
MA
Country
United States
Zip Code